Overview Fundamentals API Earnings EOD API Sample Code Pricing

Arcellx Inc (ACLX NASDAQ) stock market data APIs

$64.16 -1.76(-2.7%) as of July 16, 2024
Price chart is built with Anychart

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Arcellx Inc Financial Data Overview

65.92
64.16
-
66.58
64.16
30.88-75.1
3 389 M
53 503 K
132 M
-0.14
0.224
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ACLX',
Type: 'Common Stock',
Name: 'Arcellx Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00QHJM4S9',
ISIN: NULL,
CUSIP: NULL,
CIK: '1786205',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-02-04',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Arcellx Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 132 M
  • EBITDA -72 799 000
  • Earnings Per Share -1.03
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Arcellx Inc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.629

Get Arcellx Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com